Passive immunization with hypochlorite-oxLDL specific antibodies reduces plaque volume in LDL receptor-deficient mice

Marcella van Leeuwen1, Michael J Kemna, Menno P J de Winther

  • 1Internal Medicine, Clinical and Experimental Immunology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands.

Plos One
|July 23, 2013
PubMed
Abstract

Insights

Passive immunization with a natural IgM antibody targeting hypochlorite-oxidized low-density lipoprotein (HOCl-oxLDL) significantly reduced atherosclerosis development in mice. This suggests potential for antibody therapy in treating cardiovascular diseases.

Area of Science:

  • Immunology
  • Cardiovascular Research
  • Atherosclerosis Pathogenesis

Background:

  • Atherosclerosis is an inflammatory disease requiring new therapeutic strategies.
  • Modulating the immune system, particularly with antibodies, shows promise for treating atherosclerosis.
  • Hypochlorite-modified oxidized low-density lipoprotein (HOCl-oxLDL) is a key target in atherosclerosis.

Purpose of the Study:

  • To investigate the atheroprotective effects of passive immunization using a specific anti-HOCl-oxLDL IgM antibody.
  • To evaluate the therapeutic potential of natural IgM antibodies in mitigating atherosclerosis progression.

Main Methods:

  • Production and selection of a monoclonal mouse IgM antibody (Moab A7S8) specific for HOCl-oxLDL.
  • Induction of atherosclerosis in LDLr(-/-) mice via perivascular collar and high-fat diet.
  • Treatment of mice with Moab A7S8, irrelevant IgM, or PBS, followed by analysis of carotid arteries and aortic roots.

Main Results:

  • Passive immunization with Moab A7S8 significantly reduced atherosclerotic plaque volume compared to PBS treatment (P = 0.002 and P = 0.035).
  • Cholesterol levels decreased by 20% in mice treated with Moab A7S8.
  • Treatment with Moab A7S8 increased endogenous anti-oxLDL IgM and IgG antibody production.

Conclusions:

  • Natural IgM antibodies targeting HOCl-oxLDL demonstrate significant atheroprotective effects.
  • Specific antibody therapy holds potential for treating human cardiovascular diseases like atherosclerosis.